Work Here?
About Absci
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Vancouver, Washington
Founded
2011
Overview
AbSci focuses on improving protein expression and biomanufacturing in the biotech industry. Its main product is an advanced protein expression platform that uses a semi-oxidizing cytoplasm and a dual inducible promoter system, allowing for better control over protein production rates. This results in higher quality and efficiency in drug manufacturing. A key feature of AbSci's offerings is SoluPure, a method that simplifies protein purification without chromatography, speeding up the production process and reducing costs. Unlike traditional methods that rely on mammalian expression systems, AbSci's technology can generate cell lines producing active proteins in as little as three months. The company partners with pharmaceutical and biotech firms to provide these efficient solutions, aiming to transform drug discovery and manufacturing practices.
Simplify's Take
What believers are saying
- Absci's partnerships with AMD and Owkin enhance AI-driven drug discovery capabilities.
- Generative AI collaborations with MSK and Twist Bioscience accelerate novel therapeutic development.
- Increased adoption of AI and synthetic biology boosts Absci's innovative drug designs.
What critics are saying
- Growing competition in AI-driven drug discovery may impact Absci's market share.
- Dependence on partnerships could pose risks if collaborations don't yield results.
- Rapid tech advancements could render Absci's current technologies obsolete.
What makes Absci unique
- Absci uses AI and synthetic biology for novel protein-based drug discovery.
- Their SoluPure method simplifies protein purification, reducing production time and costs.
- Absci's high-throughput workflow generates active protein products in just three months.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$528.1M
Above
Industry Average
Funded Over
8 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
Parental Leave
401(k) Retirement Plan
401(k) Company Match
Company Equity
Employee Stock Purchase Plan
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -1%2 year growth
↑ 0%VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients. “At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI de novo design expertise with Owkin’s world-class predictive AI target discovery technology, we have a unique opportunity to design first-in-class and potentially transformative therapeutics for patients in need.” Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Owkin’s predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids
Absci Founder & CEO Sean McClain will discuss the strategic partnership at the 43rd Annual J.P.Morgan Healthcare Conference on Wednesday January 15th at 4:30pm PT.
AMD has invested $20 million in Absci Corp., an AI-driven drug discovery company. The partnership will see Absci shift some workloads to AMD's Instinct AI processors, enhancing its research capabilities. Absci will use the investment to improve its AI models and collaborate with AMD on developing new hardware and software for healthcare, focusing on drug discovery advancements.
VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) - Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct(TM) accelerators and ROCm(TM) software to power critical AI drug discovery workloads, including Absci's advanced de novo antibody design models.
Absci (NASDAQ: ABSI), a leader in AI-driven drug discovery, secured a $20 million strategic investment from Advanced Micro Devices (AMD).
Absci is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today
People Also Viewed
Discover companies similar to Absci
About Absci
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Vancouver, Washington
Founded
2011
Absci is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today
People Also Viewed
Discover companies similar to Absci